Thanks wild-1. So we win big on safety profile and get away with a draw on OS.
The next question is do we win on cost effectiveness? I've tried to find data on current treatment costs for sorafenib in US market, but the numbers are very inconsistent. Is there general agreement that SIRT treatment is considerably cheaper than sorafenib? A true analysis would also need to take into account the cost of treating side effects.
Ann: Trading Halt, page-76
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $77.74M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 18.0¢ | $10.1K | 56.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 36209025 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 4384259 | 22 |
View Market Depth
| Last trade - 15.18pm 13/09/2024 (20 minute delay) ? |
| SRX (ASX) Chart |